The FDA just approved a gene therapy after testing it on nine patients. Nine.
Kresladi, developed by Rocket Pharma, treats leukocyte adhesion deficiency type 1 (LAD-1) — a rare immune disorder where white blood cells can’t fight infections properly. Children with severe LAD-1 typically die before age two without a bone marrow transplant.
The approval breaks new ground for ultra-rare diseases. LAD-1 affects roughly one in a million births, making traditional clinical trials nearly impossible. Instead of the usual hundreds or thousands of patients, Rocket gathered data from nine children across multiple studies.
The results were compelling enough for regulators. Eight of the nine patients showed improved immune function, and several who previously suffered life-threatening infections became infection-free. The therapy works by delivering a functional copy of the ITGB2 gene directly to patients’ bone marrow stem cells.
This matters beyond LAD-1. The approval sets a precedent for treating diseases so rare that large studies are impossible. There are roughly 7,000 known rare diseases, many of them fatal in childhood. Most will never see treatments under traditional regulatory frameworks.
The longevity angle here isn’t about extending normal lifespans — it’s about giving children with LAD-1 a chance at having one. Without treatment, their immune systems can’t handle basic infections that healthy people shrug off. A simple cold can become fatal.
Gene therapy for immune disorders also hints at broader possibilities. If we can fix broken immune systems at the cellular level, the technology might eventually enhance healthy immune function or slow immune aging in the general population.
The Protocol says: This approval matters more for precedent than immediate impact. Nine patients is tiny, but FDA’s willingness to approve based on compelling rare disease data opens doors for other ultra-rare conditions with lethal outcomes.
The real story isn’t the size of the trial — it’s what happens when regulators prioritize saving lives over statistical perfection.
Based on STAT News reporting on Rocket Pharma’s FDA approval for their rare immune disorder gene therapy.